Free Trial

Smith & Nephew (SNN) Stock Forecast & Price Target

Smith & Nephew logo
$25.01 -0.20 (-0.79%)
(As of 11:45 AM ET)

Smith & Nephew - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
1

Based on 4 Wall Street analysts who have issued ratings for Smith & Nephew in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 3 have given a hold rating, and 1 has given a buy rating for SNN.

Consensus Price Target

N/A

Get the Latest News and Ratings for SNN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Smith & Nephew and its competitors.

Sign Up

SNN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy

SNN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SNN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Smith & Nephew Stock vs. The Competition

TypeSmith & NephewMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted UpsideN/A27,212.41% Upside8.86% Upside
News Sentiment Rating
Neutral News

See Recent SNN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/6/2024Berenberg Bank
2 of 5 stars
S. England
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
11/1/2024Deutsche Bank Aktiengesellschaft
3 of 5 stars
 DowngradeBuy ➝ Hold
6/5/2024UBS Group
4 of 5 stars
 UpgradeNeutral ➝ Buy
11/28/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
11/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight
10/31/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/13/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
4/11/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight
3/7/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
3/1/2023Liberum Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
12/12/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:06 PM ET.


SNN Forecast - Frequently Asked Questions

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.

According to analysts, Smith & Nephew's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Smith & Nephew's stock had 2 downgrades by analysts.

Smith & Nephew has been rated by research analysts at Berenberg Bank, and Deutsche Bank Aktiengesellschaft in the past 90 days.

Analysts like Smith & Nephew less than other "medical" companies. The consensus rating for Smith & Nephew is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNN compares to other companies.


This page (NYSE:SNN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners